Powder: -20°C for 3 years | In solvent: -80°C for 1 year
alpha-(3,4-Dihydroxyphenyl)lactic acid 具有抗氧化活性,可通过 PI3K/Akt/Nrf2 信号通路增强 HO-1 表达以抑制 6-OHDA 诱导的氧化损伤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
20 mg | ¥ 500 | 6-8周 |
产品描述 | Danshensu has antioxidant activity, can enhance HO-1 expression to suppress 6-OHDA-induced oxidative damage via PI3K/Akt/Nrf2 signaling pathways. |
激酶实验 | The recombinant HCV polymerases used in this study contain the first 570 amino acids of the 591-amino acid native protein sequence, with a six-histidine tag at the N terminus to facilitate purification by affinity chromatography. Briefly, ABT-333 (Dasabuvir) is incubated with 5 to 50 nM polymerase for 15 min at room temperature, follow by the addition of nucleoside triphosphates (NTPs) and [3H]UTP for 3 h at 30°C. After termination of the reaction, the precipitated RNA is captured by filtration through a GF/B filter. The amount of incorporated [3H]UTP is measured by scintillation counting with a Wallac 1450 MicroBeta counter. The percent inhibition is calculated from the initial rates of inhibited reactions relative to that of the uninhibited control reaction. The mean 50% inhibitory concentration (IC50) and the standard error of the mean (SEM) are calculated via nonlinear regression[1]. |
分子量 | 198.17 |
分子式 | C9H10O5 |
CAS No. | 22681-72-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Chloroform, Dichloromethane, Ethyl Acetate, Acetone, etc.: Soluble
DMSO: Soluble
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
alpha-(3,4-Dihydroxyphenyl)lactic acid 22681-72-7 oxidation-reduction Antioxidant alpha (3,4 Dihydroxyphenyl)lactic acid α-(3,4-Dihydroxyphenyl)lactic acid alpha(3,4Dihydroxyphenyl)lactic acid a-(3,4-Dihydroxyphenyl)lactic acid Inhibitor inhibitor inhibit